Antitumor Activity of Taspine by Modulating the EGFR Signaling Pathway of Erk1/2 and Akt In Vitro and In Vivo

Abstract

EGFR, as a critical signaling pathway in many human tumors, has become an important target of cancer drug design. Taspine has shown meaningful angiogenesis activity in previous studies. This paper is to investigate the antitumor action of taspine by modulating the EGFR signaling pathway. The study determined the expression of key signaling molecules of EGFR (EGFR, Akt, p-Akt, Erk, and p-Erk) by Western blot and real-time PCR and analyzed their correlations with subsequent reactions. In addition, the cell proliferation, migration, and EGF production were examined by MTT, transwell system, and ELISA. The antitumor activity in vivo was carried out by xenograft in athymic mice. The results showed that taspine could inhibit A431 and Hek293/EGFR cell proliferation and A431 cell migration as well as EGF production. Compared to the negative control, EGFR, Akt, and phosphorylation of Akt were significantly inhibited by taspine treatment in A431 and HEK293/EGFR cells. Consistent with the inhibition of Akt activity, Erk1/2 and its phosphorylation were reduced. Moreover, taspine inhibited A431 xenograft tumor growth. These results suggest that EGFR activated by EGF and its downstream signaling pathways proteins could be downregulated by taspine in a dose-dependent manner. The antitumor mechanism of taspine through the EGFR pathway lies in the ability to inhibit A431 cell proliferation and migration by reducing EGF secretion. This occurs through the repression of EGFR which mediates not only MAPK (Erk1/2) but also Akt signals.

taspine - EGFR - signaling pathway - EGFR inhibitor

References

• 1 Kerbel R S. Tumour angiogenesis: past, present and the near future.  Carcinogenesis. 2000;  21 505-515
• 2 Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer.  Curr Opin Cell Biol. 2009;  21 185-193
• 3 Yancopoulos G D, Davis S, Gale N W, Rudge J S, Wlegand S J, Holash J. Vascular-specific growth factors and blood vessel formation.  Nature. 2000;  407 242-248
• 4 Uchida C, Haas T L. Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle.  Curr Pharm Des. 2009;  15 411-421
• 5 Kelly T R, Xie R L. Total synthesis of taspine.  J Org Chem. 1998;  63 8045-8048
• 6 Perdue G P, Blomster R N, Blake D A, Farnsworth N R. South American plants II: taspine isolation and anti-inflammatory activity.  J Pharm Sci. 1979;  68 124-126
• 7 Fayad W, Fryknas M, Brnjic S, Olofsson M H, Larsson R, Linder S. Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.  PlosOne. 2009;  4 e7238
• 8 Zhang Y M, He L C, Meng L, Luo W J. Taspine isolated from Radix et Rhizoma Leonticis inhibits proliferation and migration of endothelial cells as well as chicken chorioallantoic membrane neovascularisation.  Vasc Pharmacol. 2008;  48 129-137
• 9 Zhang Y M, He L C, Meng L, Luo W J, Xu X M. Suppression of tumor-induced angiogenesis by taspine isolated from Radix et Rhizoma Leonticis and its mechanism of action in vitro.  Cancer Lett. 2008;  262 103-113
• 10 Wheatley-Price P, Shepherd F A. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.  Curr Opin Oncol. 2008;  20 162-175
• 11 Hirsch F R, Varella-Garcia M, Bunn P A, Franklin Jr. W A, Dziadziuszko R, Thatcher N. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer.  J Clin Oncol. 2006;  24 5034-5042
• 12 Kim E S, Khuri F R, Herbst R S. Epidermal growth factor receptor biology (IMC-C225).  Curr Opin Oncol. 2001;  13 506-513
• 13 Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.  J Clin Oncol. 2003;  21 2787-2799
• 14 Harichand-Herdt S, Ramalingam S S. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.  Semin Thorac Cardiovasc Surg. 2008;  20 217-223
• 15 Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy.  Clin Cancer Res. 2006;  12 5268-5272
• 16 Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, Lambertini C, Neel V, Dummer R, Wagner E F, Dotto G P. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer.  Nat Cell Biol. 2008;  10 902-911
• 17 He L C, Luo W J, Li X, Xu X M, Wang S C, Ge X W, Li C. A wild type recombined HEK293 cell of EGFR overexpression. Chinese Patent CN 200910022565.9 2009
• 18 Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.  Int J Cancer. 2002;  98 310-315
• 19 Yang Y, Marcello M, Endris V, Saffrich R, Fischer R, Trendelenburg M F, Sprengel R, Rappold G. MEGAP impedes cell migration via regulating actin and microtubule dynamics and focal complex formation.  Exp Cell Res. 2006;  312 2379-2393
• 20 Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S. Inhibition of angiogenesis by humulone, a bitter acid from beer hop.  Biochem Biophys Res Commun. 2001;  289 220-224
• 21 Takabatake D, Fujita T, Shien T, Kawasaki K, Taira N, Yoshitomi S J, Takahashi H, Ishibe Y, Ogasawara Y, Doihara H. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).  Int J Cancer. 2006;  120 181-188
• 22 Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël M J, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.  Int J Cancer. 2006;  119 2557-2566
• 23 Mou J, Fang H, Jing F, Wang Q, Liu Y, Zhu H, Xu W. Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.  Bioorg Med Chem. 2009;  17 4666-4673
• 24 Li J, Li Y, Feng Z Q, Chen X G. Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo.  Cancer Lett. 2009;  279 213-220
• 25 Sun M, Ren J, Du H, Zhang Y M, Zhang J, Wang S C, He L C. A combined A431 cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening compounds from total alkaloid of Radix Caulophylli acting on the human EGFR.  J Chromatogr B. 2010;  878 2712-2718
• 26 Adamson E D. Developmental activities of the epidermal growth factor receptor.  Curr Top Dev Biol. 1990;  24 1-29
• 27 Dutta P R, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy.  Cancer Lett. 2007;  254 165-177
• 28 Partanen A. Epidermal growth factor and transforming growth factor-alpha in the development of epithelial-mesenchymal organs of the mouse.  Curr Top Dev Biol. 1990;  24 31-55
• 29 Giannelli G, Sgarra C, Porcelli L, Azzariti A, Antonaci S, Paradiso A. EGFR and VEGFR as potential target for biological therapies in HCC cells.  Cancer Lett. 2008;  262 257-264